<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1152">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146154</url>
  </required_header>
  <id_info>
    <org_study_id>2021-1145</org_study_id>
    <nct_id>NCT05146154</nct_id>
  </id_info>
  <brief_title>Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients</brief_title>
  <official_title>Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, multiple-dose pharmacokinetic study of imipenem-relebactam&#xD;
      conducted in 12 non-infected, obese ICU patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of imipenem and relebactam</measure>
    <time_frame>6 months</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of imipenem and relebactam</measure>
    <time_frame>6 months</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of imipenem and relebactam</measure>
    <time_frame>6 months</time_frame>
    <description>Total body clearance (CLt)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of imipenem and relebactam</measure>
    <time_frame>6 months</time_frame>
    <description>Apparent volume of distribution (Vd)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of imipenem and relebactam</measure>
    <time_frame>6 months</time_frame>
    <description>Monitoring for adverse drug events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Obesity</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetic cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After at least 2 doses of study drug, serial blood samples will be collected from 12 non-infected, obese ICU patients to evaluate the pharmacokinetics of imipenem and relebactam in this population.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After at least 2 doses of study drug, safety will be monitored closely during study drug dosing and through 72 hours after the last dose is administered in the same 12 non-infected, obese ICU patients from the PK arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem/Cilastatin/Relebactam 1.25g</intervention_name>
    <description>Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.</description>
    <arm_group_label>Pharmacokinetic cohort</arm_group_label>
    <arm_group_label>Safety cohort</arm_group_label>
    <other_name>Recarbrio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years of age&#xD;
&#xD;
          2. Admitted to the ICU&#xD;
&#xD;
          3. BMI ≥40 kg/m2 and/or total body weight ≥120 kg&#xD;
&#xD;
          4. Provide a signed and dated written informed consent prior to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of significant hypersensitivity reaction or intolerance to imipenem/cilastatin&#xD;
             or carbapenem-based agents (doripenem, ertapenem, or meropenem +/- vaborbactam)&#xD;
&#xD;
          2. History of seizures and/or receiving 1 or more anti-epileptic agent&#xD;
&#xD;
          3. Serum creatinine ≥1.5 mg/dL&#xD;
&#xD;
          4. Estimated creatinine clearance (CLCR) &lt;60 mL/minute as determined by Cockcroft-Gault&#xD;
             equation:&#xD;
&#xD;
          5. Actively receiving antimicrobial therapy for treatment of a confirmed or suspected&#xD;
             infection&#xD;
&#xD;
          6. The subject has participated in a clinical trial and has received a drug or a new&#xD;
             chemical entity within 30 days prior to the first dose of study medication&#xD;
&#xD;
          7. Positive serum pregnancy test (for women of childbearing potential)&#xD;
&#xD;
          8. Currently breast feeding&#xD;
&#xD;
          9. Has previously participated in this study&#xD;
&#xD;
         10. Concomitant use of valproic acid or divalproex sodium&#xD;
&#xD;
         11. Any other condition that may make the patient unsuitable for the study in the&#xD;
             judgement of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Wenzler, PharmD</last_name>
    <phone>3129967440</phone>
    <email>wenzler@uic.edu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 13, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Eric R Wenzler</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Relebactam</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

